IGF-1 LR3 is a long-acting analogue of Insulin-like Growth Factor 1, studied for anabolic, tissue repair, and metabolic effects. Physician-reviewed. Prescription required.
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor 1, modified to have longer half-life (~20–30 hours) and reduced binding to IGF-binding proteins (IGFBPs). IGF-1 LR3 acts as a direct anabolic and mitogenic growth factor, primarily through activation of the IGF-1 receptor (IGF1R).
IGF-1 LR3 has been studied for its role in muscle protein synthesis, cell growth, glucose metabolism, and tissue repair. Its reduced IGFBP binding increases bioavailability and potency compared to native IGF-1. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| IGF1R activation | Protein synthesis, cell growth, survival |
| PI3K/AKT/mTOR signaling | Muscle hypertrophy, tissue repair |
| Ras/MAPK pathway | Cell proliferation and differentiation |
| Reduced IGFBP binding | Increased bioavailability and potency |
| Anti-apoptotic effects | Protection of cells during stress |
| Glucose metabolism modulation | Enhanced glucose uptake and glycogen synthesis |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with IGF-1 LR3 protocol candidates in clinical practice:
Muscle Development
Individuals pursuing physician-supervised anabolic support for lean mass development.
Tissue Repair
Individuals recovering from significant musculoskeletal injury requiring intensive tissue repair support.
Performance Athletes
High-output athletes under physician supervision seeking advanced recovery and performance support.
Metabolic Support
Individuals with metabolic goals where IGF-1 mediated glucose utilization may be clinically relevant.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
20–100 mcg/day
Administration
Subcutaneous injection
Duration
4–8 weeks (physician-determined)
Frequency
Once daily (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your IGF-1 LR3 protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
IGF-LR3 (Insulin-Like Growth Factor 1 Long R3) is used for muscle growth, fat loss, enhanced recovery, and cellular repair. It is significantly more potent than natural IGF-1 with a longer half-life.
HGH stimulates the liver to produce IGF-1. IGF-LR3 is a modified, more potent form of IGF-1 that works directly at the cellular level and resists binding proteins, resulting in stronger effects.
Benefits include accelerated muscle protein synthesis, improved fat oxidation, faster post-workout recovery, enhanced joint and connective tissue health, and anti-aging cellular effects.
IGF-LR3 is a subcutaneous or intramuscular injectable at Verum Health. Due to its potency, physician oversight and careful dosing are essential.